Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 2/20 | 0.51 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.44 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.41 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20288566 | 0.95 | CALCRL (0.51) | CALCRLSSTR3SIRT1SIRT2ECE1 | |
| SCHEMBL23868672 | 0.93 | CALCRL (0.50) | CALCRLSSTR3SIRT1SIRT2ECE1 | |
| SCHEMBL26016683 | 0.89 | CALCRL (0.51) | CALCRLSSTR3SIRT1SIRT2ECE1 | |
| SCHEMBL19455828 | 0.80 | OPRK1 (0.44) | CALCRLSSTR3 | |
| SCHEMBL24829473 | 0.80 | SSTR3 (0.57) | CALCRLSSTR3SIRT1SIRT2SIRT3 | |
| SCHEMBL23651238 | 0.79 | CALCRL (0.51) | CALCRLSSTR3ECE1HDAC8MMP3 | |
| SCHEMBL23651237 | 0.79 | CALCRL (0.51) | CALCRLSSTR3ECE1HDAC8MMP3 | |
| SCHEMBL21653415 | 0.79 | SIRT2 (0.41) | SIRT1SIRT2SIRT3 | |
| SCHEMBL17490754 | 0.79 | SSTR3 (0.54) | CALCRLSSTR3SIRT1SIRT2SIRT3 | |
| SCHEMBL24472056 | 0.78 | SSTR3 (0.55) | CALCRLSSTR3SIRT1SIRT2ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542332-B2 | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof | BIOATLA, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11518812-B2 | Monoclonal antibodies against HER2 epitope and methods of use thereof | MERSANA THERAPEUTICS, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-11254742-B2 | Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof | BIOATLA, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210403577-A1 | ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES AND USES THEREOF | BIOATLA, INC. (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210403565-A1 | ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof | BIOATLA, INC. (US) | 2021-12-30 | — | — | US | disclosed |
| US-10435471-B2 | Anti-FcRH5 antibodies | GENENTECH, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180015179-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| US-20170326248-A1 | ANTI-CD22 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC (US) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326248-A1 | ANTI-CD22 ANTIBODIES AND IMMUNOCONJUGATES | CD22, CD2, CD2BP2 | CALCRL 1428/4885SSTR3 1595/4885SIRT1 3576/4885 |
| US-11542332-B2 | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof | CD274, IGLV6-57, PDCD1LG2 | CALCRL 410/4885SSTR3 1657/4885SIRT1 3854/4885 |
| US-11518812-B2 | Monoclonal antibodies against HER2 epitope and methods of use thereof | ERBB2, EGFR, ERBB3 | CALCRL 1949/4885SSTR3 454/4885SIRT1 4346/4885 |
| US-20210403577-A1 | ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES AND USES THEREOF | AXL, ERBB3, TYRO3 | CALCRL 1444/4885SSTR3 258/4885SIRT1 1951/4885 |
| US-20180015179-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES | CD79B, CD99, CD47 | CALCRL 2655/4885SSTR3 2572/4885SIRT1 4814/4885 |
| US-10435471-B2 | Anti-FcRH5 antibodies | FCGR3B, FCGRT, FCGR1A | CALCRL 1159/4885SSTR3 616/4885SIRT1 4850/4885 |
| US-11254742-B2 | Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof | RORB, RORA, RORC | CALCRL 2120/4885SSTR3 2704/4885SIRT1 3833/4885 |
| US-20210403565-A1 | ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof | CD274, IGLV6-57, PDCD1LG2 | CALCRL 410/4885SSTR3 1657/4885SIRT1 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.